FIG. 1.

LY333531 treatment decreases PKCβ₂ phosphorylation and iNOS in cardiomyocytes. A: (top) Representative Western blot showing phospho-PKCβ₂ (Thr⁶⁴¹) in comparison with total PKCβ₂ in cardiomyocytes exposed to low glucose (LG; 5.5 mmol/l) or high glucose (HG; 25 mmol/l) for 18 h in the absence or presence of LY333531 (LY333531; 20 nmol/l). (bottom) The densitometric values of phospho-PKCβ₂ were normalized to corresponding total PKCβ₂ densitometric values and the relative band intensities are expressed as means ± SE (n = 4 independent experiments). *P < 0.05 compared with low glucose, low glucose + LY333531, and high glucose + LY333531 groups. B: Representative Western blot showing iNOS expression, with glyceraldehyde-3-phosphate dehydrogenase (GADPH) as a loading control, in cardiomyocytes exposed to low (5.5 mmol/l) or high glucose (25 mmol/l) for 18 h in the presence or absence of LY333531 (20 nmol/l). iNOS densitometric values were normalized to their corresponding GAPDH densitometric values and expressed as relative band intensities. All data are expressed as means ± SE (n = 3 to 5 independent experiments). *P < 0.05 compared with low glucose, low glucose + LY333531, and high glucose + LY333531 groups.